The purpose of this study is: * to find out out the number of children who develop crohn's disease (CD) and ulcerative colitis (UC) each year and are living with the disease and to see how this differs by age groups. * to understand how children of different age groups are treated over time and how their treatment changes as they grow. * to assess how often children use healthcare services and how much this costs for different age groups over several years. CD and UC are long-term diseases that cause inflammation in intestine (part of digestive system) and develop ulcers.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Crude and Age-Adjusted Annual Incidence in Pediatric Crohn's Disease (CD)
Timeframe: During the index period (2012 to 2023; up to 12 years)
Crude and Age-Adjusted Annual Incidence in Pediatric Ulcerative Colitis (UC)
Timeframe: During the index period (2012 to 2023; up to 12 years)
Crude and Age-Adjusted Annual Prevalence in Pediatric CD
Timeframe: During the index period (2012 to 2023; up to 12 years)
Crude and Age-Adjusted Annual Prevalence in Pediatric UC
Timeframe: During the index period (2012 to 2023; up to 12 years)
Incidence of CD by Age-Stratified Groups
Timeframe: During the index period (2012 to 2023; up to 12 years)
Incidence of UC by Age-Stratified Groups
Timeframe: During the index period (2012 to 2023; up to 12 years)
Prevalence of CD by Age-Stratified Groups
Timeframe: During the index period (2012 to 2023; up to 12 years)
Prevalence of UC by Age-Stratified Groups
Timeframe: During the index period (2012 to 2023; up to 12 years)
Percentage of Participants Whose Primary Diagnosis Switched Between CD and UC
Timeframe: During the index period (2012 to 2023; up to 12 years)
Initial Treatment Types by Age-Stratified Group
Timeframe: From index date to follow-up (Up to 13 years)
Subsequent Treatment Sequences by Age-Stratified Group
Timeframe: From index date to follow-up (Up to 13 years)
Cumulative Persistence Rates for Biologic Drugs
Timeframe: From index date to follow-up (Up to 13 years)
Time to Discontinuation
Timeframe: From index date to follow-up (Up to 13 years)
Number of Hospitalizations
Timeframe: From index date to follow-up (Up to 13 years)
Length of Hospitalization
Timeframe: From index date to follow-up (Up to 13 years)
Number of Emergency Department (ED) Visit
Timeframe: From index date to follow-up (Up to 13 years)
Number of Outpatient Visits
Timeframe: From index date to follow-up (Up to 13 years)
Number of Inflammatory Bowel Disease (IBD) Related Surgeries
Timeframe: From index date to follow-up (Up to 13 years)
Number of Inpatient and Outpatient Visits to Non-Gastroenterology (GI) Departments
Timeframe: From index date to follow-up (Up to 13 years)
Medical Costs
Timeframe: From index date to follow-up (Up to 13 years)